Clinical Trial Update: ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update for ZD 1839 in hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ZD 1839

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED